Related references
Note: Only part of the references are listed.Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1
Heba Alshaker et al.
ONCOTARGET (2016)
Cellular and molecular effects of the mTOR inhibitor everolimus
Uttara Saran et al.
CLINICAL SCIENCE (2015)
Sphingosine kinase 1 contributes to leptin-induced STAT3 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer
Heba Alshaker et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment
Nicolas Kozakowski et al.
TARGETED ONCOLOGY (2014)
SPHK1 regulates proliferation and survival responses in triple-negative breast cancer
Arpita Datta et al.
ONCOTARGET (2014)
Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway
Heba Alshaker et al.
BREAST CANCER RESEARCH (2014)
mTOR in breast cancer: Differential expression in triple-negative and non-triple-negative tumors
S. Walsh et al.
BREAST (2012)
Sphingosine-1-Phosphate Produced by Sphingosine Kinase 1 Promotes Breast Cancer Progression by Stimulating Angiogenesis and Lymphangiogenesis
Masayuki Nagahashi et al.
CANCER RESEARCH (2012)
Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies
S. Murray et al.
CANCER TREATMENT REVIEWS (2012)
Effects of the combination of RAD001 and docetaxel on breast cancer stem cells
Xiaobei Zhang et al.
EUROPEAN JOURNAL OF CANCER (2012)
Overcoming docetaxel resistance in prostate cancer: a perspective review
Clara Hwang
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
Overcoming Chemotherapy Resistance in Prostate Cancer
Ravi A. Madan et al.
CLINICAL CANCER RESEARCH (2011)
The involvement of sphingosine kinase 1 in LPS-induced Toll-like receptor 4-mediated accumulation of HIF-1α protein, activation of ASK1 and production of the pro-inflammatory cytokine IL-6
Dmitri Pchejetski et al.
IMMUNOLOGY AND CELL BIOLOGY (2011)
Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer
Dmitri Pchejetski et al.
NATURE REVIEWS UROLOGY (2011)
FTY720 (Fingolimod) Sensitizes Prostate Cancer Cells to Radiotherapy by Inhibition of Sphingosine Kinase-1
Dmitri Pchejetski et al.
CANCER RESEARCH (2010)
Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: A new paradigm for understanding the therapeutic effect of combined treatment
Cecile Ortholan et al.
EUROPEAN JOURNAL OF CANCER (2010)
Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens
Bernard Malavaud et al.
EUROPEAN JOURNAL OF CANCER (2010)
mToR signaling and drug development in cancer
Janet Dancey
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Sphingosine 1-phosphate induces vesicular endothelial growth factor expression in endothelial cells
Kyun Heo et al.
BMB REPORTS (2009)
Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel
Lysann Sauer et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
R. Bianco et al.
BRITISH JOURNAL OF CANCER (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models
Dimitri Pchejetski et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Antianglogenic potential of the mammalian target of rapamycin inhibitor temsirolimus
Donatella Del Bufalo et al.
CANCER RESEARCH (2006)
Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models
D Pchejetski et al.
CANCER RESEARCH (2005)
Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer
M Liu et al.
CANCER RESEARCH (2005)
The evolving role of docetaxel in the management of androgen independent prostate cancer
MA Khan et al.
JOURNAL OF UROLOGY (2003)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation - A dominant-negative sphingosine kinase
SM Pitson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
